The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

Blood

Volumn 126, Issue 3, 2015, Pages 328-335

  Witzig, Thomas E ^a   Reeder, Craig ^b   Han, Jing Jing ^a   LaPlant, Betsy ^a   Stenson, Mary ^a   Tun, Han W ^c   Macon, William ^a   Ansell, Stephen M ^a   Habermann, Thomas M ^a   Inwards, David J ^a   Micallef, Ivana N ^a   Johnston, Patrick B ^a   Porrata, Luis F ^a   Colgan, Joseph P ^a   Markovic, Svetomir ^a   Nowakowski, Grzegorz S ^a   Gupta, Mamta ^a  

^a MAYO CLINIC ROCHESTER   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MTOR PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IN VITRO STUDY; LARGE CELL LYMPHOMA; LYMPHATIC LEUKEMIA; LYMPHOCYTE PROLIFERATION; MALE; MYCOSIS FUNGOIDES; NATURAL KILLER T CELL; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; T LYMPHOCYTE; THROMBOCYTE COUNT; TREATMENT RESPONSE; VERY ELDERLY; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BLOOD; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFECTS; FLOW CYTOMETRY; LYMPHOMA, T-CELL; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR RECURRENCE; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CYTOKINES; EVEROLIMUS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IN VITRO TECHNIQUES; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; MULTIPROTEIN COMPLEXES; NEOPLASM RECURRENCE, LOCAL; PHOSPHORYLATION; PROGNOSIS; SIROLIMUS; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84937798468     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-02-629543     Document Type: Article

References (35)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29.
2. Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31(29):3688-3695.
3. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516.
4. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
5. O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182-1189.
6. Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631-636.
7. Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(29):4485-4491.
8. Foss F, Advani R, Duvic M, et al. A phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015;168(6):811-819.
9. Briski R, Feldman AL, Bailey NG, et al. The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. Blood Cancer J. 2014;4:e214.
10. Gopal AK, Kahl BS, de Vos S, et al. PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008-1018.
11. Kahl BS, Spurgeon SE, Furman RR, et al. A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014;123(22):3398-3405.
12. Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood. 2009;114(14):2926-2935.
13. Ghobrial IM, Gertz M, Laplant B, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010;28(8):1408-1414.
14. Ghobrial IM, Witzig TE, Gertz M, et al. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. Am J Hematol. 2014;89(3):237-242.
15. Johnston PB, Inwards DJ, Colgan JP, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85(5):320-324.
16. Witzig TE, Reeder CB, LaPlant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011;25(2):341-347.
17. Zent CS, LaPlant BR, Johnston PB, et al. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer. 2010;116(9):2201-2207.
18. Ansell SM, Inwards DJ, Rowland KM Jr, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer. 2008;113(3):508-514.
19. Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol. 2011;12(4):361-368.
20. Inwards DJ, Fishkin PA, LaPlant BR, et al. Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. Ann Oncol. 2014;25(10):2020-2024.
21. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23(23):5347-5356.
22. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/ T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-4130.
23. Gupta M, Dillon SR, Ziesmer SC, et al. A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase- regulated mammalian target of rapamycin activation. Blood. 2009;113(21):5206-5216.
24. Hu G, Witzig TE, Gupta M. A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling. PLoS ONE. 2013;8(7):e67851.
25. Sonbol MB, Maurer MJ, Stenson MJ, et al. Elevated soluble IL-2Ra, IL-8, and MIP-1b levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma. Am J Hematol. 2014;89(12): E223-E227.
26. Cheson BD, Horning SJ, Coiffier B, et al NCI Sponsored International Working Group. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17(4):1244-1253.
27. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958; 53:457-481.
28. Olsen E, Vonderheid E, Pimpinelli N, et al ISCL/EORTC. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713-1722.
29. Hsieh AC, Ruggero D. Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clin Cancer Res. 2010;16(20):4914-4920.
30. Briski R, Feldman AL, Bailey NG, et al. Survival in patients with limited-stage peripheral T-cell lymphomas [published online ahead of print October 30, 2014]. Leuk Lymphoma. 2014;1-6.
31. Ramirez-Fort MK, Case EC, Rosen AC, Cerci FB, Wu S, Lacouture ME. Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis. Am J Clin Oncol. 2014;37(3):266-271.
32. Xu J, Tian D. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis. Curr Med Res Opin. 2014;30(1):67-74.
33. Lopez P, Kohler S, Dimri S. Interstitial lung disease associated with mTOR inhibitors in solid organ transplant recipients: results from a large phase III clinical trial program of everolimus and review of the literature. J Transplant. 2014. doi:10.1155/2014/305931.
34. Ramakrishnan V, Timm M, Haug JL, et al. Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. Am J Hematol. 2012;87(3):277-283.
35. Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ, Koeffler HP. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia. 2007;21(2):333-339.